As an investigator for LEADER, what features of this study with respect to CV and mortality outcomes deserve special emphasis? How do they differ from other CV outcome trials in diabetes?

As an investigator for LEADER, what features of this study with respect to CV and mortality outcomes deserve special emphasis? How do they differ from other CV outcome trials in diabetes?

As an investigator for LEADER, what features of this study with respect to CV and mortality outcomes deserve special emphasis? How do they differ from other CV outcome trials in diabetes?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Luc Van Gaal, MD

Luc Van Gaal, MD

Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium